Company Description
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People’s Republic of China.
The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.
It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies.
Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
| Country | China |
| Founded | 2012 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Haimei Wu |
Contact Details
Address: Baide Building, Building 11, Room 202, 2/F Guangzhou China | |
| Phone | 86 20 8218 5926 |
| Website | bairdmed.com |
Stock Details
| Ticker Symbol | BDMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1982444 |
| CUSIP Number | G0705H103 |
| ISIN Number | KYG0705H1039 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mark S. Saxton | Chief Executive Officer U.S. Subsidiary |
| Haimei Wu | Chairwoman of the Board of Directors and Chief Executive Officer |
| Quan Qiu | Chief Administrative Officer and Executive Director |
| Wei Hou | Executive Director |
| Jie Li | Acting Chief Financial Officer |
| Rongjian Lu | Chief Technology Officer and Deputy GM |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 3, 2026 | 6-K | Report of foreign issuer |
| Aug 18, 2026 | 424B3 | Prospectus |
| Aug 17, 2026 | EFFECT | Notice of Effectiveness |
| Aug 17, 2026 | EFFECT | Notice of Effectiveness |
| Aug 6, 2026 | POS AM | Post-Effective amendments for registration statement |
| Aug 6, 2026 | F-3/A | Filing |
| Jul 31, 2026 | SCHEDULE 13D | Filing |
| Jul 27, 2026 | 20-F/A | Filing |
| May 22, 2026 | POS AM | Post-Effective amendments for registration statement |
| May 22, 2026 | F-3 | Filing |